NEW BIOMARKERS FOR ACUTE MYELOID LEUKEMIA

摘要

The present invention relates to a method for predicting the survival time of a patient suffering from acute myeloid leukemia (AML) and treated with cytarabine and/or anthracycline comprising i) determining in a sample obtained from the patient the gene expression level of at least 1 gene selected from the group consisting of CHK1 and POLQ ii) comparing the gene expression level determined at step i) with its predetermined reference value and iii) providing a good prognosis when the expression level determined at step i) is lower than its predetermined reference value, or providing a bad prognosis when the expression level determined at step i) is higher than its predetermined reference value. The invention also relates to an i) inhibitor of Chk1 or an inhibitor of the CHK1 gene expression, and ii) an inhibitor of Pol theta or an inhibitor of the POLQ gene expression, as a combined preparation for simultaneous, separate or sequential for use in the treatment of acute myeloid leukemia (AML).